Literature DB >> 31383534

When Should we Irradiate the Primary in Metastatic Lung Cancer?

A-M Shiarli1, F McDonald2, D R Gomez3.   

Abstract

Metastatic lung cancer encompasses a heterogenous group of patients in terms of burdens of disease, ranging from patients with extensive metastases to those with a limited number of metastatic lesions (oligometastatic disease). Histopathological heterogeneity also exists within two broad categories, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), portraying different patterns and evolution of disease. Local consolidative therapy to the primary tumour and metastatic sites, including surgery and/or radical dose radiotherapy, is increasingly being used to improve survival outcomes, particularly in the context of oligometastatic disease, with or without the use of molecular targeted therapy and immunotherapy. Recently, randomised studies in oligometastatic NSCLC have shown that local consolidative therapy may confer a survival advantage. This review explores whether treating just the primary tumour with radiotherapy may similarly produce improved clinical outcomes. Such a treatment strategy may carry less potential toxicity than treating multiple sites upfront. The biological rationale behind the potential benefits of treating just the primary in metastatic malignancy is discussed. The clinical evidence of such an approach across tumour sites, such as breast and prostate cancer, is also explored. Then the review focuses on treating the primary in NSCLC and SCLC with radiotherapy, by first exploring patterns of failure in metastatic NSCLC and second exploring evidence on survival outcomes from studies in metastatic NSCLC and SCLC. It is challenging to draw conclusions on the clinical benefit of treating the primary cancer in isolation from the evidence available. This highlights the need to collect data within the ongoing clinical trials on the clinical outcome and toxicity of radiotherapy delivery to primary thoracic disease specifically. This challenge also identifies the need to design future clinical trials to produce randomised evidence for such an approach.
Copyright © 2019 The Royal College of Radiologists. All rights reserved.

Entities:  

Keywords:  Lung cancer; non-small cell lung cancer; oligometastatic disease; primary tumour; radiotherapy; small cell lung cancer

Mesh:

Year:  2019        PMID: 31383534     DOI: 10.1016/j.clon.2019.07.012

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  1 in total

Review 1.  [Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics].

Authors:  Xinghao Ai; Yong Cai; Qian Chu; Chengbo Han; You Lu; Songbing Qin; Lin Wu; Conghua Xie; Zhiyong Yuan; Wenzhao Zhong; Xiaoxia Zhu; Joe Y Chang; Zhengfei Zhu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.